PTG-300 in Subjects With Hereditary Hemochromatosis

Exclusion Criteria

• •Clinically meaningful laboratory abnormality
• •Receiving iron chelation therapy
• •Receiving erythrocytapheresis
• •Pregnant or lactating females
• •Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infections requiring antimicrobial therapy within 4 weeks of dosing.
• •Serious or unstable medical or psychiatric condition that would prevent subject providing informed consent
• •Organ damage from iron overload
• •Primary or secondary immunodeficiency
• •Positive hepatitis B or hepatitis C or known human immunodeficiency virus infection
• •Known history of autoimmune/inflammatory diseases
• •Any surgical procedures requiring general anesthesia within 1 month prior to screening or planned surgery during study
• •History of invasive malignancies within last 2 years, except non-malignant skin cancer and local cured prostate cancer, cervical cancer, or ductal carcinoma in situ
• •Receipt of an investigational agent within 30 days of screening